[1] Dar A,Ma S,Rittsteuer C,et al. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression[J]. Natl Cancer Inst,2013,105(6):433-442.[2] Cookson VJ,Bentley MA,Hogan BV,et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours[J].Cell Oncol,2012,35(4):301-308.[3] Fonseca-Sanchez MA,Perez-Plasencia C,Fernandez-Retana J,et al. microRNA-18b is upregulated in breast cancer and modulates genes involved in cell migration[J]. Oncol Rep,2013,30(5):2399-2410.[4] Siegel R,Naishadham D,Jemal A,et al. Cancer statistics[J].CA Cancer Clin,2013,63(1):11-30.[5] Yadav BS,Sharma SC,Chanana P,et al.Systemic treatment strategies for triple-negative breast cancer[J]. Clin Oncol,2014,5(2):125-133.[6] Hoeferlin LA,E Chalfant C,Park MA. Challenges in the treatment of triple negative and HER2-overexpressing breast cancer[J]. Surg Sci,2013,1(1):3-7.[7] Sirohi B. Amedos M,Popat S,et al. Platinum based chemotherapy in triple negative breast carcer[J].Ann Oncol,2008,19(11):1847-1852.[8] Bouchalova K,Kharaishvili G,Bouchal J,et al. Triple negative breast cancer-BCL2 in prognosis and prediction[J]. Review,2014,15(12):1166-1175.[9] 石永国,卞卫和,何烨,等. miR-206对三阴性乳腺癌细胞的增殖抑制作用及初步机制研究[J]. 临床肿瘤学杂志,2013,18(12):1062-1065.[10] Zhao Z,Li R,Sha S,et al. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation[J].Cancer Biol Ther,2014,15(10):1404-1412.[11] Bischoff A,Huck B,Keller B,et al. miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion[J]. Cancer Res,2014,74(18):5256-5265.[12] 项丹,姜藻,顾晓怡. 西达本胺联合顺铂对三阴性乳腺癌细胞株MDA-MB-231的体外抗增殖作用及其机制的研究[J]. 东南大学学报:医学版,2013,32(3):283-288.[13] 张梦怡,陈鹰,陈建华,等.多肽P161联合顺铂对乳腺癌 MA-782 细胞株增殖和凋亡的影响[J].中国药师,2013,16(12):1768-1771.[14] Bennett PE,Bemis L,Norris DA,et al. miR in melanoma development:miRNAs and acquired hallmarks of cancer melanoma[J].Physiol Genomics,2013,45(22):1049-1059.[15] Murakami Y,Tamori A,Itami S. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis[J].BMC Cancer,2013,99(13):1471-1482.[16] 章国晶,郭放,谢晓东.2012版美国国立综合癌症网络乳腺癌指南更新要点及研究进展荟萃[J].中国实用内科杂志,2013,33(2):127-130.[17] 史中平,周建荣.乳腺化疗相关症状随疗程的变化趋势[J].中国老年学杂志,2013,33(10):2346-2348. |